enGene Therapeutics (ENGN) Times Interest Earned (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Times Interest Earned of -$2.94 for Q2 2026, up 51.48% year-over-year from -$1.94 in Q2 2025, and up 93.09% quarter-over-quarter from -$42.6 in Q1 2026.
enGene Therapeutics (ENGN) Times Interest Earned (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Times Interest Earned for 4 consecutive years, with -$2.94 the latest figure, recorded in Q2 2026.
- In Q2 2026, Times Interest Earned rose 51.48% year-over-year to -$2.94; the TTM figure through Apr 2026 stood at -$12.2 (up 37.94% YoY), while the FY2025 annual figure was -$11.22, down 782.23% from the prior year.
- Times Interest Earned advanced to -$2.94 in Q2 2026 per ENGN's latest filing, from -$42.6 in the prior quarter.
- Across five years, Times Interest Earned topped out at $5221.0 in Q4 2023 and bottomed at -$110.47 in Q4 2024.
- Historically, Times Interest Earned has averaged $354.22 across 4 years, with a median of -$5.2 in 2023.
- Annual changes were most pronounced in 2024 — Times Interest Earned soared 89.56% — and 2025, when it slumped 1342.63%.
- enGene Therapeutics' Times Interest Earned stood at $5221.0 in 2023, then tumbled by 102.12% to -$110.47 in 2024, then soared by 74.76% to -$27.88 in 2025, then soared by 89.45% to -$2.94 in 2026.
- Business Quant data shows ENGN's Times Interest Earned at -$2.94 in Q2 2026, -$42.6 in Q1 2026, and -$27.88 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | -42.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.94 |
| Jan 31, 2026 | -42.60 |
| Oct 31, 2025 | -27.88 |
| Jul 31, 2025 | -7.25 |
| Apr 30, 2025 | -6.06 |
| Jan 31, 2025 | -33.27 |
| Oct 31, 2024 | -110.47 |
| Jul 31, 2024 | -0.81 |
| Apr 30, 2024 | -0.42 |
| Jan 31, 2024 | -17.96 |
| Oct 31, 2023 | 5,221.00 |
| Jul 31, 2023 | -4.33 |
| Apr 30, 2023 | -4.02 |
| Jan 31, 2023 | -3.94 |